[시장보고서]SGLT2 억제제 시장 규모, 점유율, 동향 분석 보고서 : 의약품별, 적응증별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

SGLT2 억제제 시장 규모, 점유율, 동향 분석 보고서 : 의약품별, 적응증별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Type 2 Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1813856

리서치사 : Grand View Research

발행일 : 2025년 08월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,649,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,103,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,010,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

SGLT2 억제제 시장 요약

SGLT2 억제제 세계 시장 규모는 2024년 168억 달러로 추정되며, 2025-2033년 연평균 6.19% 성장하여 2033년에는 289억 달러에 달할 것으로 예측됩니다.

2형 당뇨병과 동반질환에 사용되는 이들 약제는 혈당 조절과 심혈관 위험 감소에 효과적이기 때문에 높은 수요가 있습니다.

이 시장은 심혈관질환, 만성신장질환 등 동반질환과 함께 전 세계적으로 2형 당뇨병 유병률 증가로 인해 크게 성장하고 있습니다. 국제당뇨병연맹(IDF)에 따르면, 2024년 전 세계적으로 약 5억 8,900만 명의 성인이 당뇨병을 앓고 있었으며, 이 수치는 2050년까지 8억 5,300만 명으로 증가할 것으로 예상되고 있습니다. 이러한 당뇨병의 부담 증가로 의료계는 보다 효과적인 치료법을 찾고 있으며, 그 중에서도 SGLT2 억제제는 혈당 조절과 심혈관 보호라는 두 가지 장점을 가지고 있어 인기를 끌고 있습니다. 엠파글리플로진, 다파글리플로진 등의 약물은 당뇨병 환자의 심혈관 사망 및 심부전으로 인한 입원 감소에 큰 효과를 보이고 있습니다. 또한, SGLT2 억제제가 만성 신장 질환 치료에 있어 SGLT2 억제제의 역할이 인식되면서 시장 수요가 더욱 증가하고 있으며, FDA의 비당뇨병 환자의 만성 신장 질환에 대한 다파글리플로진의 승인은 2020년 적응증 확대의 핵심이 될 것으로 보입니다.

시장 계통 전망
- 상위 시장 전망
- 관련/부수 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
SGLT2 억제제 시장 분석 툴
- 업계 분석 - Porter의 Five Forces 분석
- PESTEL 분석
- 파이프라인 분석
- 대상 집단 분석

제4장 SGLT2 억제제 시장 : 의약품 추정 및 동향 분석

세계의 SGLT2 억제제 시장 : 의약품 대시보드
세계의 SGLT2 억제제 시장 : 의약품 변동 분석
SGLT2 억제제 세계 시장(약제별, 매출별)
Jardiance (empagliflozin)
Farxiga (dapagliflozin)
Invokana (canagliflozin)
Inpefa (sotagliflozin)
Qtern (dapagliflozin/saxagliptin)
기타 SGLT2 억제제

제5장 SGLT2 억제제 시장 : 적응증 추정 및 동향 분석

세계의 SGLT2 억제제 시장 : 적응증 대시보드
세계의 SGLT2 억제제 시장 : 적응증 변동 분석
적응증별 매출
2형 당뇨병
심혈관계
만성 신장병(CKD)
기타

제6장 SGLT2 억제제 시장 : 유통 채널 추정 및 동향 분석

세계의 SGLT2 억제제 시장 : 유통 채널 대시보드
세계의 SGLT2 억제제 시장 : 유통 채널 변동 분석
유통 채널별 매출
병원 약국
소매 약국
온라인 약국

제7장 SGLT2 억제제 시장 : 약제, 적응증, 유통 채널별 지역 추정 및 동향 분석

지역 대시보드
시장 규모, 예측 동향 분석, 2021년-2033년 :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업의 최근 동향과 영향 분석
기업/경쟁 분류
벤더 구도
- 주요 유통업체 및 채널 파트너 리스트
- Key customers
- Key company market share analysis, 2023
- Boehringer Ingelheim International GmbH.
- AstraZeneca
- Merck &Co., Inc.
- Johnson &Johnson Services, Inc.(Janssen Pharmaceuticals, Inc.)
- TheracosBio, LLC
- Lexicon Pharmaceuticals, Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Glenmark Pharmaceuticals Ltd

LSH

영문 목차

영문목차

SGLT2 Inhibitors Market Summary

The global SGLT2 inhibitors market size was estimated at USD 16.8 billion in 2024 and is projected to reach USD 28.9 billion by 2033, growing at a CAGR of 6.19% from 2025 to 2033. These drugs, used for Type 2 diabetes and comorbidities, are in high demand due to their effectiveness in glycemic control and cardiovascular risk reduction.

The market is experiencing significant growth due to the increasing global prevalence of Type 2 diabetes, along with related comorbidities such as cardiovascular diseases and chronic kidney disease. According to the International Diabetes Federation (IDF), nearly 589 million adults worldwide were living with diabetes in 2024, a figure that is expected to rise to 853 million by 2050. This growing burden of diabetes is prompting healthcare systems to seek more effective treatment options, with SGLT2 inhibitors gaining popularity due to their dual benefits of glycemic control and cardiovascular protection. These drugs, such as empagliflozin and dapagliflozin, have shown significant efficacy in reducing cardiovascular mortality and hospitalizations for heart failure in diabetic patients. Furthermore, the increasing recognition of the role of SGLT2 inhibitors in treating chronic kidney disease is driving further market demand, with the FDA's approval of dapagliflozin for chronic kidney disease in non-diabetic patients marking a notable expansion of its indications in 2020.

Global SGLT2 Inhibitors Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global SGLT2 Inhibitors market report based on drug, indication, distribution channel,and region:

Drug Outlook (Revenue, USD Million, 2021 - 2033)
Jardiance (empagliflozin)
Farxiga (dapagliflozin)
Invokana (canagliflozin)
Inpefa (sotagliflozin)
Qtern (dapagliflozin/saxagliptin)
Other SGLT2 Inhibitors
Indication Outlook (Revenue, USD Million, 2021 - 2033)
Type 2 Diabetes
Cardiovascular
Chronic Kidney Disease (CKD)
Others
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Kuwait
- UAE

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug
- 1.2.2. Indication
- 1.2.3. Distribution Channel
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Drug and Indication outlook
- 2.2.2. Distribution Channel outlook
- 2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing prevalence of target disease
  - 3.2.1.2. Technological advancements in drug development
  - 3.2.1.3. Growing awareness and diagnosis
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High cost of drug development
  - 3.2.2.2. Stringent regulatory policies for drug approval
3.3. SGLT2 Inhibitors Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
- 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
4.4. Jardiance (empagliflozin)
- 4.4.1. Jardiance (empagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Farxiga (dapagliflozin)
- 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Invokana (canagliflozin)
- 4.6.1. Invokana (canagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Inpefa (sotagliflozin)
- 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
4.8. Qtern (dapagliflozin/saxagliptin)
- 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts, 2021 - 2033 (USD Million)
4.9. Other SGLT2 Inhibitors
- 4.9.1. Other SGLT2 inhibitors market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
5.4. Type 2 Diabetes
- 5.4.1. Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Cardiovascular
- 5.5.1. Cardiovascular market estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Chronic Kidney Disease (CKD)
- 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts, 2021 - 2033 (USD Million)
5.7. Others
- 5.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Mexico
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Regulatory framework/ reimbursement structure
  - 7.3.3.3. Competitive scenario
  - 7.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. Boehringer Ingelheim International GmbH.
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Product benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. AstraZeneca
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Product benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. Merck & Co., Inc.
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Product benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Product benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. TheracosBio, LLC
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Product benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. Lexicon Pharmaceuticals, Inc.
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Product benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Eli Lilly and Company
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Product benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11. Bristol-Myers Squibb Company
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Product benchmarking
  - 8.3.11.4. Strategic initiatives
- 8.3.12. Glenmark Pharmaceuticals Ltd
  - 8.3.12.1. Company overview
  - 8.3.12.2. Financial performance
  - 8.3.12.3. Product benchmarking
  - 8.3.12.4. Strategic initiatives